...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Liquidity
4
Jan 21, 2016 06:56PM
5
Jan 21, 2016 07:20PM
1
Jan 22, 2016 09:36AM
1
Jan 22, 2016 05:05PM
4
Jan 22, 2016 05:36PM
4
Jan 22, 2016 06:36PM
4
Jan 24, 2016 11:53AM
5
Jan 24, 2016 12:49PM

Hi fouremm.

Thanks for the perspective. I think we all know that body language represents at least 80% plus of communications. So the fact that you and masila were there and you seem quite optimistic provides some reassurance to me. We all want to see both RVX and ZCC succeed. I knew I was getting into very high risk investing 8 years ago and I've lost a lot of money on paper but I dollar cost averaged down and remain long. I have not sold RVX.

I do believe in their science. The scientific publication in the journal of Atherosclerosis by RVX about rvx-208 (as posted by BDAZ) is a clear sign of scientific momentum behind the approach of both companies. This is very exciting because it gives credibility beyond the analysts.

If the prostate trial on 12 men with metastisis shows positive signs I do feel that interest and development will accelerate.

However, I do get very frustrated when Don creates expectations on the business side that he does not live up to. The science side IMHO seems to be in very good shape.

So I guess we'll see. I have no concerns about the science and the momentum that is building at RVX/ZEL and the scientific community at large. The Hepalink deal on the business side is also a major victory and potentially new leverage against BP. A second deal would dramatically enhance interest from investors.

The Pats lost but Denver ruled and I like them as well.

GLTA

Toinv

Share
New Message
Please login to post a reply